BioMarin beats Q2 expectations on strong enzyme therapy sales and raises full-year earnings and revenue guidance amid continued Voxzogo growth.
Latest Ratings for BMRN
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | Piper Sandler | Maintains | Overweight | |
| Nov 2021 | Credit Suisse | Maintains | Outperform | |
| Nov 2021 | Morgan Stanley | Maintains | Equal-Weight |
